Ultragenyx Pharma (RARE) Tops Q3 EPS by 22c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. WCN
6. SPOT
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Ultragenyx Pharma (RARE) Tops Q3 EPS by 22c, Revenues Beat

Ultragenyx Reports Third Quarter 2018 Financial Results and Corporate Update

November 5, 2018 4:05 PM EST

NOVATO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results and corporate update for the quarter ended September 30, 2018.

Were encouraged by the growing demand for Crysvita from both children and adults with XLH in the United States, and we are making significant progress reaching doctors and helping them get patients on commercially available therapy in this early launch phase, said Emil D. Kakkis, M.D., Ph.D., Chief... More